Effektivnost' immunosupressivnoy i antikoagulyantnoy terapii u bol'noy granulematozom s poliangiitom i kriofibrinogenemiey
- Authors: Shevtsova T.P1, Novikov P.I1, Smitienko I.O1, Meshkov A.D1, Moiseev S.V1
-
Affiliations:
- Issue: No 19 (2014)
- Pages: 43-47
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287539
- ID: 287539
Cite item
Abstract
Full Text
About the authors
T. P Shevtsova
Email: TPShevcova@gmail.com
P. I Novikov
Email: novikov-pavel@mail.ru
I. O Smitienko
A. D Meshkov
Email: alexeymeshkov@mail.ru
S. V Moiseev
Email: clinpharm@mtu-net.ru
References
- Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013; 1: 70-4.
- Новиков П.И., Моисеев С.В., Кузнецова Е.И., Семенкова Е.Н., Мухин Н.А. Изменения течения заболевания и прогноза гранулематоза с полиангиитом (Вегенера): результаты 40-летнего наблюдения. Клиническая фармакология и терапия. 2014; 1: 32-7
- Моисеев С.В., Новиков П.И., Мешков А.Д., Иваницкий Л.В. АНЦА-ассоциированные васкулиты: спорные вопросы классификации, диагностики и оценки активности и современные подходы к лечению. Клиническая фармакология и терапия. 2014; 1: 44-50.
- Новиков П.И., Моисеев С.В., Буланов Н.М., Макаров Е.А. Современные подходы к терапии АНЦА-ассоциированных системных васкулитов. Клиническая нефрология. 2014; 1: 42-9.
- Allenbach Y., Seror R., Pagnoux C., et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann. Rheum. Dis. 2009; 68(4): 564-67.
- Soyfoo M.S., Goubella A., Cogan E., et al. clinical significance of cryofibrinogenemia: possible pathophysiological link with Raynaud's phenomenon. J. Rheumatol. 2011; 39: 119-24.
- Sebastian J.K., Voetsch B., Stone J.H., et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J. Rheumatol. 2007; 34: 2446-50.
- Lamprecht P., de Groot K., Schnabel A., et al. Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegener's granulomatosis. Rheumatology. 2000; 39: 568-70.
- Merkel P.A., Chang Y., Pierangeli S.S., et al. The prevalence and clinical association of anticar-diolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am. J. Med. 1996; 101: 576-83.
- Korst D.R., Kratochvil C.H. Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood. 1955; 10: 945-53.
- Vermeersch P., Gijbels K., Marien G., et al. A Critical Appraisal of Current Practice in the Detection, Analysis, and Reporting of Cryoglobulins. Clin. Chem. 2008; 54: 1: 39-43.
- Smith R.T., Von Korff R.W. A heparin-precipitable fraction of human plasma. I. Isolation and characterization of the fraction. J. Clin. Investig. 1957; 36: 596-604.
- Smith R.T. A heparin-precipitable fraction of human plasma. Occurrence and significance of the fraction in normal individuals and in various disease states. J. Clin. Investig. 1957; 36: 605-16.
- Martin M., Pourrat J. Cryofibrinogenaemia. J. Clin. Rheumatol. 2013; 19(3): 142-48.
- Blain H., Cacoub P., Musset L., et al. Cryofibrinogenaemia: a study of 49 patients. Clin. Exp. Immunol. 2000; 120: 253-60.
- Saadoun D., Elalamy I., Ghillani-Dalbin P., et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am. J. Med. 2009; 122: 1128-35.
- Amdo T.D., Welker J.A. An approach to the diagnosis and treatment of cryofibrinogenemia. Am. J. Med. 2004; 116: 332-37.
- Saadoun D., Musset L., Cacoub P. Cryofibrinogenemia. Rev. Med. Interne Fondee. 2010; 32: 287-91.
- Belizna C., Loufrani L., Subra J.F., et al. A 5-year prospective follow-up study in essential cryo fibrinogenemia patients. Autoimmune Rev. 2011; 10: 559-62.
- Belizna C.C., Tron F., Joly P., et al. Outcome of essential cryofibrinogenaemia in a series of 61 patients. Rheumatology. 2008; 47: 205-7.
- Nash J.W., Ross P. Jr, Neil Crowson A., et al. The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am. J. Clin. Pathol. 2003; 119: 114-22.
- Terrier B., Izzedine H., Musset L., et al. Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders. Nephrol. Dial. Transplant. 2011; 26: 3577-81.
- Zlotnick A., Shahin W., Rachmilewitz E.A. Studies in cryofibrinogenemia. Acta Haematol. 1969; 42: 8-17.
- McKee P.A., Bird R.M. Incidence and significance of cryofibrinogenemia. J. Lab. Clin. Med. 1962; 61: 203-10.
- Sawada K., Takahashi R., Saniabadi A.R., et al. Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous. World J. Gastroenterol. 2006; 12: 1621-25.
- Kuipers J.G., Kellett J., May D. Low levels of cryofibrinogenaemia and peripheral circulatory dysfunction. Irish Med. J. 1991; 84: 68-9.
- Nagy J., Ambrus M., Paal M., et al. Cryoglobulinaemia and cryofibrinogenaemia in IgA nephropathy: a follow-up study. Nephron. 1987; 46: 337-42.
- Stathakis N.E., Karamanolis D., Koukoulis G., et al. Characterization of cryofibrinogen isolated from patients plasma. Haemostasis. 1981; 10: 195-202.
- Smith S.B., Arkin C. Cryofibrinogenemia: incidence, clinical correlations, and a review of the literature. Am. J. Clin. Pathol. 1972; 58: 524 -30.
- Rachmilewitz E.A., Sacks M.I., Zlotnick A. Essential cryofibrinogenemia. Clinical, pathological and immunological studies. Isr. J. Med. Sci. 1970; 6: 32-43.
- Jantunen E., Soppi E., Neittaanmaki H., et al. Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura. J. Intern. Med. 1993; 234: 331-33.
- Kirsner R.S., Eaglstein W.H., Katz M.H., et al. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J. Am. Acad. Dermatol. 1993; 28: 71-4.
- Revenga F., Aguilar C., Gonzalez R., et al. Cryofibrinogenaemia with a good response to stanozolol. Clin. Exp. Dermatol. 2000; 25: 621-23.
- Williamson A.E., Cone L.A., Huard G.S. 2nd. Spontaneous necrosis of the skin associated with cryofibrinogenemia, cryoglobulinemia, and homocystinuria. Ann. Vasc. Surg. 1996; 10: 365-69.
- Helfman T., Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J. Am. Acad. Dermatol. 1995; 33: 254-58.
- Euler H.H., Zeuner R.A., Beress R., et al. Monoclonal cryo-antifibrinogenemia. Arthritis Rheum. 1996; 39: 1066-69.
- Copeman P.W. Cryofibrinogenaemia and skin ulcers: treatment with plasmapheresis. Br. J. Dermatol. 1979; 101(Suppl 17): 57-8.
- Sankarasubbaiyan S., Scott G., Holley J.L. Cryofibrinogenemia: an addition to the differential diagnosis of calciphylaxis in end-stage renal disease. Am. J. Kidney Dis. 1998; 32: 494-98.
- Browning C.E., Callen J.P. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch. Dermatol. 2006; 142: 75-8.
- Beightler E., Diven D.G., Sanchez R.L., et al. Thrombotic vasculopathy associated with cryofibrinogenemia. J. Am. Acad. Dermatol. 1991; 24: 342-45.